January 25, 2012 — Preoperative magnetic resonance imaging (MRI) helps surgeons make more informed decisions about nerve-sparing procedures in men with prostate cancer, according to a new study published online in the journal Radiology.

January 25, 2012 — International medical technology company, Sectra announces its multi-year agreement with Nashville General Hospital at Meharry.

Study findings presented during the San Antonio Breast Cancer Symposium (SABCS) in December, stating that brachytherapy was associated with a twofold increased risk for mastectomy and complications, garnered almost immediate reaction from several industry groups, questioning that claim.


The next big advancement in cardiac imaging is likely to be computed tomography (CT) perfusion imaging. This enables one commonly available modality to image both the detailed anatomy and function of the heart at the same time. The impact on medicine could reduce healthcare costs by eliminating some hospital stays, cutting the number of tests and speeding patient diagnosis.

On five Saturdays each year, 100 women make their way to the Susan G. Komen for the Cure Tissue Bank at the Indiana University Simon Cancer Center to take part in the battle against breast cancer.

January 23, 2012 — In treatments of only the first handful of patients with lung or liver tumors, Riverside and University of Virginia Radiosurgery Center in Newport News, Va., clinicians have demonstrated the benefit that Elekta's Symmetry 4-D image guidance technology provides for patients whose tumors move with their breathing.

January 23, 2012 — Radcal Corporation announced that the Leeds Test Objects cone beam computed tomography (CBCT) SedentexCT Mini phantom was available for sales within the United States.

January 20, 2012 – Nuclear cardiology imaging company Positron Corp. this week acquired Manhattan Isotope Technology LLC (MIT). Positron has acquired all of the assets, business operations and retained all employees of MIT. In exchange, MIT shall receive cash advances, assumption of certain indebtedness and earn-out consideration of $3.5 million based on 20 percent of the net income from sales relating to radioisotope and radiopharmaceutical operations of MIT.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now